Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026)

Recursion Pharmaceuticals has reported Research & Development for 7 years, with the latest figure at $87.9 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 32.2% year-over-year to $87.9 million; the trailing twelve-month figure through Mar 2026 stood at $433.5 million (up 15.15% YoY), and the FY2025 full-year result was $475.3 million, up 51.16% from the prior year.
• Research & Development for Q1 2026 stood at $87.9 million, down from $95.9 million in the prior quarter.
• The five-year high for Research & Development was $129.6 million in Q1 2025, with the low at $32.4 million in Q1 2022.
• Historically, Research & Development has averaged $75.0 million across 5 years, with a median of $70.0 million in 2023.
• Annual changes were most pronounced in 2025 — Research & Development surged 91.88% — and 2026, when it plunged 32.2%.
• Recursion Pharmaceuticals' Research & Development stood at $44.0 million in 2022, then soared by 57.99% to $69.5 million in 2023, then jumped by 41.52% to $98.3 million in 2024, then fell by 2.43% to $95.9 million in 2025, then dropped by 8.38% to $87.9 million in 2026.
• The last three Research & Development figures came in at $87.9 million (Q1 2026), $95.9 million (Q4 2025), and $121.1 million (Q3 2025), per Business Quant data.